In an interview with OncLive®, UT Southwestern’s Dr. David Miller, Professor of Obstetrics and Gynecology in the Division of Gynecologic Oncology, expanded on the importance of investigating outcomes with selinexor in TP53 wild-type patients with endometrial cancer; reported key efficacy, safety, and quality-adjusted survival data in this patient population from the SIENDO trial; and highlighted the ongoing phase 3 ENGOT-EN20/GOG-3083/XPORT-EC-042 trial (NCT05611931) designed to confirm these findings for potential regulatory approval.